ANXA5 and acute myeloid leukemia: In four AML cell lines, HL-60, ML-2, MOLM-13 and MV4-11, we analyzed CD11b and annexin-V for up to 8 days, observing a progressive increase in CD11b expression, achieving differentiation levels close to 90% in all cases after 6–8 days of treatment (Fig. 2B and Supplementary Fig. 2A).